OncTimes Talk

OncTimes Talk

By Oncology TimesMedicineHealth & Fitness
Download on the App Store

OncTimes Talk episodes

  • Unpacking the Role of Emotions in Mastectomy Decisions with Clara N. Lee, MD

    A bilateral prophylactic mastectomy for women at high risk of developing breast cancer can reduce their risk of developing the disease by up to 90 percent, according to the National Cancer Institute. An increasing number of women, including young women, are taking up this option. And while the data shows mastectomy is an effective method of reducing breast cancer risk, doctors still have to consider patients' choices which often involve other factors. For the individual patient, choosing a mastectomy is a complex non-linear process that is affected by personal knowledge, past experiences, and emotions surrounding identity and societal expectation. To understand these factors more, Oncology Times interviewed Clara N. Lee, MD, Associate Professor of plastic and reconstructive surgery at The Ohio State University College of Medicine. Lee’s clinical practice focuses on breast reconstruction and microvascular surgery and her research focuses on understanding and improving how people with cancer make decisions about surgery. She recently authored a paper titled “The Role of Emotion in Cancer Surgery Decisions: Applying Concepts From Decision Psychology” published in the Annals of Surgery (2021; doi: 10.1097/SLA.0000000000004574). She has expertise in patient-reported outcomes for breast reconstruction and patient decision-making about breast cancer treatments. We discussed a bit of her

    research into the emotional journeys of patients who are deciding whether to proceed with contralateral prophylactic mastectomy

    23 min
  • Mitigating the Effects of Climate Change on Cancer Care With Robert A. Hiatt, MD, PhD

    While the threat of climate change may conjure images of sea level rise, extreme weather patterns, and drought, the full picture of how climate change will impact oncology practice and care is still emerging. We do know that climate change will impact cancer risk, increase exposure to carcinogens, impede access to care, and ultimately effect survival. To discuss some of these impending changes and what oncologists and patients can do to prepare, Oncology Times interviewed Robert A. Hiatt, MD, PhD, Professor in the Department of Epidemiology and Biostatistics, and Associate Director of Population Sciences at the UCSF Helen Diller Family Comprehensive Cancer Center.

    16 min
  • Roswell Park’s Candace S. Johnson & Congressman Brian Higgins on the Promise of Biden’s Cancer Moonshot

    In early February, President Joe Biden announced that he is supercharging the Cancer Moonshot program to accelerate progress against cancer and save lives. The ambitious, jumpstarted Cancer Moonshot aims to reduce the U.S. death rate due to cancer by at least 50 percent over the next 25 years, and to improve the lives of all Americans living with and surviving cancer. The recharged Cancer Moonshot calls for a bipartisan across-the-board, all-hands-on-deck U.S. effort, which includes establishing a “Cancer Cabinet” consisting of the heads of major government agencies. Biden is asking Congress to approve $6 billion net new money to advance promising new treatments. In a press briefing in early February, Candace Johnson, PhD, the President and CEO of Roswell Park Comprehensive Cancer Center discussed the reinvigorated Moonshots program with Congressman Brian Higgins (D-NY 26th District). Roswell Park Comprehensive Cancer Center will benefit from the newly announced federal Cancer Moonshot Initiative and Representative Brian Higgins said the center was selected because of its extraordinary background in cancer research and treatment.

    15 min
  • ASH 2021 Revisited: Plenary Sessions, ZUMA-7 & COVID Vaccines

    Today we revisit three studies presented at the ASH 2021 Annual Meeting. Primary Analysis of ZUMA-7 The 2021 American Society of Hematology Plenary Sessions in Atlanta, Georgia, heard data from a new study of CAR-T cell therapy in patients with diffuse large B-cell lymphoma: the Phase III randomized ZUMA-7 trial. This compared Axicabtagene Ciloleucel (Axi-Cell) with the current standard-of-care in patients whose disease had relapsed or was refractory after first-line therapy. After the talk, Oncology Times reporter Peter Goodwin caught up with the lead investigator Frederick Locke, MD, Co-Leader of the Immuno-Oncology Program, and Vice Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at the Moffitt Cancer Center in Tampa, FL. How Patients with AML & MDS Respond to COVID Vaccines ASH 2021 held a cluster of sessions devoted to coronavirus infection in patients with hematologic malignancies.

    Since cancer patients in general are at higher risk from COVID-19 than the general population, it has become vitally important to know whether vaccines can protect them. Vaccine responses in patients with myelodysplastic syndrome and acute myeloid leukemia have been investigated by a team led by Jeffrey Lancet, MD, Chair of Malignant Hematology at the Moffit Cancer Center in Tampa, Florida. Oncology Times reporter Peter Goodwin asked him about his findings. Antibody Response to Vaccination Whether or not to vaccinate your patient for COVID-19 may not be obvious in some clinical situations, and in hematologic malignancy this cannot be assumed. At ASH, German investigator Susanne Saussele, MD, reported her group’s findings about vaccination responses in patients with a range of myeloid and lymphoid malignancies. She is Head of the CML Excellence Center III. Medizinische Klinik, Hematology and Oncology at the University of Mannheim in Mannheim, Germany.

    42 min
  • ASH 2021 Recap: Multi Omics Sheds New Light on Malignant Transformation from Myeloproliferative Neoplasm to AML

    In this episode, we bring you new research from the 2021 American Society of Hematology Annual Meeting about the cellular processes involving the mutated TP53 oncogene that can convert a patient’s—fairly benign—myeloproliferative neoplasm into a very threatening acute myeloid leukemia. These have been under investigation at Oxford University in the UK, using the refined genetic sequencing tool: single cell multi omics (Abstract 3). The ASH Plenary Session heard an inspiring talk on this from Oxford scientist Alba Rodriguez-Meira—winner of an ASH Abstract Achievement Award. And after the session, OT reporter Peter Goodwin tracked down her colleague, senior author Adam J. Meade, at the Weatherall Institute of Molecular Medicine in Oxford University.

    18 min
  • OncTimes Talk Research Review February 2022: Dr. Stephen Hahn, COVID, 2021 World Cancer Leaders’ Summit & Cervical Cancer News

    Today we are bringing you a round up of three stories from around the world. We will start at the 2021 World Cancer Leader’s Summit, then move onto a story on how radiotherapy can cut late gastrointestinal toxicity for cervical cancer patients, and finish with lessons on what COVID has taught us about cancer care. All interviews are brought to you by journalist Peter Goodwin. First up, we hear from radiation oncologist Stephen Hahn, MD, who was the U.S. Food and Drug Administration's Commissioner from 2019 to 2021—where he oversaw all manner of regulations concerning COVID-19 vaccines and therapeutics. In his 2021 address at the World Cancer Leaders' Summit, Hahn discussed "What can we learn from the development of COVID-19 vaccines." During the summit, leading cancer decision-makers from about a hundred countries met online to assess whether innovations generated during the pandemic of COVID-19 could be harnessed to improve cancer

    treatment and prevention. Journalist Peter Goodwin was curious to know about decision-making at the FDA during this crucial period of American history. Next, from Mumbai, India—there's news that the new adjuvant radiotherapy standard of care for cervical cancer—image-guided intensity-modulated radiotherapy (IG-IMRT)—should cut late gastrointestinal (GI) toxicity rates by 50 percent. This according to mature results from the Phase III, randomized Postoperative Adjuvant Radiation in Cervical Cancer (PARCER) study. Although IG-IMRT is a newer—more costly—form of radiotherapy that has already been shown to reduce early toxicity rates to some extent when compared with conventional three-dimensional conformal radiation therapy (3D-CRT), up until now it had not been shown to outperform the older technique either in terms of medium-term toxicity or anti-cancer activity. The PARCER findings, however, demonstrate clear superiority for long term GI toxicity. They confirm equivalent anti-neoplastic efficacy. Peter Goodwin interviewed first author Supriya Chopra MD, DNB, from the Tata Memorial Centre’s Homi Bhabha National Institute in Kharghar near Mumbai, India. She discusses the strong mandate that the study has brought for choosing IG-IMRT adjuvant radiotherapy for patients with early cervical cancer in whom surgery is needed. Lastly, The COVID-19 pandemic has taught us a lot about cancer care—according to one of India's most prominent oncologists, C.S. Pramesh, MS FRCS, Director of the Tata Memorial Centre in Mumbai, India. He also spoke at the 2021 World Cancer Leaders’ Summit, organized by the Union for International Cancer Control, and hosted virtually by the American Society for Clinical Pathology. After the meeting OncTimes Talk reporter Peter Goodwin caught up with him to ask for his take on the impact the pandemic has had on cancer medicine, and about his views on how to improve medical practice and cope better with future crises.

    1 hr 7 min
  • ASH 2021 Recap: COVID-19 in Patients with Acute Leukemias & Myelodysplasia In Conversation with Dr. Pinkal Desai

    At the 2021 Annual Meeting of the American Society of Hematology, researchers presented more data on additional risks faced by patients who have acute leukemia or myelodysplastic syndrome and have become infected with COVID-19. In a key study presented at ASH, Dr. Pinkal Desai from New York’s Weill Cornell Medical College has identified clinical predictors of outcome among these patients. Oncology Times reporter Peter Goodwin talked with Dr. Desai about her findings and clinical recommendations.

    19 min
  • Study Recap: After 6 Months, Pfizer COVID Vaccine Remains Effective Against Hospitalizations

    A new study provides support for high effectiveness of the Pfizer COVID vaccine against hospital admissions up until around 6 months after being fully vaccinated. The real-world, retrospective cohort study included data from 3.4 million Californian residents and was recently published in The Lancet. 

    The importance of this Californian study is that up until now we've mainly relied on phase three study results to assess vaccine efficacy. This study (and another, even bigger one in Chile—with the CoronaVac) brings much greater statistical significance to the outcome findings and makes it possible to look at subgroups.

    In this episode, Lead author Dr. Sara Y Tartof, a Research Scientist Epidemiologist with Kaiser Permanente Department of Research & Evaluation in Southern California discusses the implications for vaccination programs with Oncology Times reporter Peter Goodwin.

    15 min
  • Research Spotlight: MET Amplification as Driver for NSCLC

    A new study has helped to define MET amplification as a rare but potentially actionable driver for non-small cell lung cancer (NSCLC). The paper, titled “Crizotinib in Patients With MET-Amplified NSCLC,” published in the Journal of Thoracic Oncology, introduces a third means of defining NSCLC subsets that can be targeted with a specific drug. In this episode, journalist Peter Goodwin interviews study author D. Ross Camidge, MD, PhD, Director of Thoracic Oncology at the University of Colorado School of Medicine, on the recent findings.

    17 min
  • Colleague Conversations: Palliative Care in Oncology

    Colleague Conversations offers insights into hematology/ oncology from two different perspectives: a seasoned hematologist/oncologist and an early-career clinician. In this installment, Oncology Times sat down with Christopher A. Jones, MD, MBA, HMDC, FAAHPM, and David Jonathan Casarett, MD, MA, FAAHPM, to discuss the relatively new field of palliative care. The discussion leads us through how the field has transformed oncology care, how palliative care physicians can address issues like racial disparities, and how telehealth is the wave of the future.

    21 min

About OncTimes Talk

From the publisher's feed

OncTimes Talk features a variety of podcast series ranging from breaking news and oncology conference coverage to story round-ups and in-depth interviews with current experts and leaders in oncology.